Determining vitamin B6 status, including in persons who present with progressive nerve compression disorders, such as carpal tunnel and tarsal tunnel syndromes
Determining the overall success of a vitamin B6 supplementation program
Diagnosis and evaluation of hypophosphatasia
Test Id | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
PLP | Pyridoxal 5-Phosphate (PLP), P | Yes | Yes |
B6PA | Pyridoxic Acid (PA), P | No | Yes |
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
P 5-P
Pyridoxal Phosphate
Soft- B6PRO
Vitamin B6
Pyridoxal 5-Phosphate (PALP)
Plasma Heparin
Patient Preparation:
1. Patient should fast overnight (12-14 hours); infants-should have specimen collected before next feeding. Water can be taken as needed.
2. For 24 hours before specimen collection, patient must not take multivitamins or vitamin supplements.
Supplies: Amber Frosted Tube, 5 mL (T915)
Collection Container/Tube: Green top (sodium or lithium heparin) or plasma gel separator (PST)
Submission Container/Tube: Amber vial
Specimen Volume: 1 mL
Collection Instructions:
1. Centrifuge at 4 degrees C within 2 hours of collection.
2. Aliquot all plasma into amber vial and freeze immediately.
0.75 mL
Gross hemolysis | OK |
Gross lipemia | OK |
Gross icterus | OK |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Plasma Heparin | Frozen | 29 days | LIGHT PROTECTED |
Determining vitamin B6 status, including in persons who present with progressive nerve compression disorders, such as carpal tunnel and tarsal tunnel syndromes
Determining the overall success of a vitamin B6 supplementation program
Diagnosis and evaluation of hypophosphatasia
Vitamin B6 is a complex of 6 vitamers: pyridoxal, pyridoxol, pyridoxamine, and their 5'-phosphate esters. Due to its role as a cofactor in many enzymatic reactions, pyridoxal 5-phosphate (PLP) has been determined to be the biologically active form of vitamin B6.
Vitamin B6 deficiency is a potential cause of burning mouth syndrome and a possible potentiating factor for carpal tunnel and tarsal tunnel syndromes. Persons who present with chronic, progressive nerve compression disorders may be deficient in vitamin B6 and should be evaluated. Vitamin B6 deficiency is associated with symptoms of scaling of the skin, severe gingivitis, irritability, weakness, depression, dizziness, peripheral neuropathy, and seizures. In the pediatric population, deficiencies have been characterized by diarrhea, anemia, and seizures.
Markedly elevated PLP in conjunction with low levels of pyridoxic acid are observed in cases of hypophosphatasia, a disorder characterized by low levels of alkaline phosphatase and a range of skeletal abnormalities.
PYRIDOXAL 5-PHOSPHATE
5-50 mcg/L
PYRIDOXIC ACID
3-30 mcg/L
Levels for fasting individuals falling in the range of 3 to 30 mcg/L for pyridoxic acid (PA) and 5 to 50 mcg/L for pyridoxal 5-phosphate (PLP) are indicative of adequate nutrition.
The following are interpretative guidelines based on PLP and PA results:
If PLP is >100 mcg/L and PA is < or =30 mcg/L:
-The increased PLP is suggestive of hypophosphatasia. Consider analysis of serum alkaline phosphatase isoenzymes (ALKI / Alkaline Phosphatase, Total and Isoenzymes, Serum) and urinary phosphoethanolamine (AAPD / Amino Acids, Quantitative, Random, Urine)
If PLP is >100 mcg/L and PA is 31 to 100 mcg/L or PLP is 81 to 100 mcg/L and PA is < or =30 mcg/L:
-The increased PLP is likely related to dietary supplementation; however, a mild expression of hypophosphatasia cannot be excluded. Consider analysis of serum alkaline phosphatase isoenzymes (ALKI / Alkaline Phosphatase, Total and Isoenzymes, Serum) and urinary phosphoethanolamine (AAPD / Amino Acids, Quantitative, Random, Urine).
If PLP is 51 to 80 mcg/L or PLP is 81 to 100 mcg/L and PA is >30 mcg/L or PLP is >100 mcg/L and PA is >100 mcg/L:
-The elevated PLP is likely due to dietary supplementation.
Reference ranges were established using healthy fasting volunteers who abstained from vitamin supplementation for 24 hours prior to specimen collection. Vitamin supplementation and nonfasting may result in elevated plasma vitamin concentrations.
1. Kimura M, Kanehira K, Yokoi K. Highly sensitive and simple liquid chromatographic determination in plasma of B6 vitamins, especially pyridoxal 5'-phosphate. J Chromatogr A. 1996;722(1-2):296-301. doi:10.1016/0021-9673(95)00354-1
2. Ball GFM, ed: Vitamins: Their Role in the Human Body. Blackwell Publishing; 2004:310-325
3. Mackey AD, Davis SR, Gregory JF III: Vitamin B6. In: Shils ME, Shike M, Ross AC, et al. eds. Modern Nutrition in Health and Disease. 10th ed. Lippincott Williams and Wilkins; 2006:452-461
4. Roberts NB. Taylor A. Sodi R: Vitamins and trace elements. In: Rifai N, Horvath AR, Wittwer CT, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Elsevier; 2018:639-718
The stable isotope pyridoxal 5-phosphate-d2 and/or pyridoxic acid-d2 is added to plasma as an internal standard. Meta-phosphoric acid solution is then added to precipitate the proteins. Following sedimentation of the proteins, an aliquot of the clarified supernatant fluid is subjected to separation of pyridoxal 5-phosphate, pyridoxic acid, and internal standards from other plasma components by reverse-phase high-performance liquid chromatography with quantitation by tandem mass spectrometry.(Unpublished Mayo method)
Monday through Thursday, Saturday, Sunday
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
82542
84207
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
B6PRO | Vitamin B6 Profile (PLP and PA), P | 95266-3 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
61065 | Pyridoxic Acid (PA), P | 1688-1 |
4047 | Pyridoxal 5-Phosphate (PLP), P | 30552-4 |